Androgen deprivation therapy (ADT) is a staple of treatment for prostate cancer, but a recent study adds to a growing body of evidence that it places men at higher risk of cognitive decline.
Men in the United States have about a one in seven chance of being diagnosed with prostate cancer during their lifetimes, according to the American Cancer Society. For decades, clinicians have used ADT to treat the disease. The treatment reduces the levels of androgens — primarily testosterone and dihydrotestosterone — in the body or prevents them from reaching the prostate, where they stimulate the growth of both normal and cancer-causing cells. Approximately half a million prostate cancer patients in the United States receive ADT.
The past several years, studies have found an association between ADT and reduced cognitive function. In 2015, researchers led by Kevin T. Nead, MD, MPhil, a resident in the Department of Radiation Oncology at the University of Pennsylvania Perelman School of Medicine and a fellow at the Leonard Davis Institute of Health Economics at the University of Pennsylvania, and Nigam Shah, MBBS, PhD, Associate Professor of Biomedical Informatics Research at Stanford University School of Medicine, found that prostate cancer patients who underwent ADT were nearly twice as likely to develop Alzheimer’s disease as patients who did not have the treatment. Risk correlated with treatment duration: Men who received ADT the longest had the highest risk of Alzheimer’s.
“When we published [that study], a letter to the editor pointed out that Alzheimer’s is often confused with vascular dementia,” Dr. Shah says in a Stanford press release. “So instead of looking for Alzheimer’s and dementia separately, we decided to aggregate them into a higher-level category — all dementias and cognitive decline.”
Depriving the Body of Testosterone’s Protection
To investigate ADT’s effect on all dementias, Drs. Nead and Shah and colleagues conducted a retrospective study using the EHRs of nearly 10,000 Stanford Medicine prostate cancer patients. Slightly more than 1,800 of the patients had undergone ADT. Individuals who had the treatment were more than twice as likely to develop dementia within five years as those who did not have it; nearly 8 percent of ADT patients went on to have dementia, whereas only 3.5 percent of non-ADT patients did.
“No matter how we looked at the data, we saw a strong association between ADT and dementia,” says Dr. Nead, the lead author.
ADT-associated cognitive sequelae can happen quickly. A 2015 Moffitt Cancer Center study found that patients who had ADT were more likely to experience mental impairment six months after treatment than non-ADT patients. Dr. Nead theorizes the treatment, by lowering testosterone levels, may rob the body of some of the androgen’s critical benefits.
“Testosterone and testosterone analogues have been shown to be directly neuroprotective,” he says. “Low testosterone and ADT have also been shown to increase cardiometabolic disease, which is an independent risk factor for dementia, by impacting neurovascular function. Through these mechanisms, ADT may globally decrease neurovascular function, thereby increasing the risk of dementia.”
The next step in exploring ADT’s association with dementia is to conduct a prospective study to confirm causality and stratify risk, Dr. Nead says.
Catalyst for Clinical Conversation
Many questions about the link between ADT and dementia remain.
“We need to learn more about which specific types of ADT raise risk of cognitive impairment the most,” says Brian D. Gonzalez, PhD, Assistant Member at the Moffitt Cancer Center. Gonzalez was the lead author of the 2015 Moffitt study but was not involved with the 2016 Penn and Stanford study. “We also need to find out which participants are at greatest risk. I’m working to design studies that would take a personalized medicine approach to finding which men are at risk under which conditions based on their genotype, age, previous history, ADT regimen, behavior patterns and other factors.”
Clinicians should thoroughly discuss ADT’s risks and benefits with patients, not stop prescribing it, Dr. Gonzalez says. Dr. Nead agrees.
“Based on the body of literature that now exists, it would be reasonable to counsel patients regarding potential cognitive risks,” he says. “We would, however, not recommend specific changes to clinical practice based on this study alone, given that ADT is a life-extending treatment in some men with prostate cancer.”